Numab Reacquires Advanced Compound from Sucampo
Antibody Pipeline Focused on Severe Asthma
WÄDENSWIL, Switzerland -- October 29, 2013
Numab AG, a company focused on the discovery and development of innovative
antibody-based therapeutics, announced today that it has reacquired the rights
to ND003, a bispecific anti-IL5RxCD3 antibody fragment for the targeted lysis
of eosinophils in severe asthma, from Sucampo AG, a subsidiary of Sucampo
Pharmaceuticals, Inc. (Nasdaq:SCMP).
“ND003 is being developed for topical administration to the lung in patients
suffering from severe asthma,” said David Urech, CSO and co-CEO of Numab.
“Current marketed or development stage antibody drugs in severe and refractory
asthma are given systemically and fail to effectively reach the lung tissue.
Based on its targeted and highly potent mechanism of action ND003 is developed
to overcome these challenges and is poised to greatly reduce the morbidity and
mortality of severe asthma sufferers. Together with our autoimmune disease
program ND007 we now have two potential breakthrough drugs in our pipeline.”
IL5R as a target, and the depletion of eosinophils have already been
clinically validated in asthma (for instance with benralizumab). However, an
important differentiator of ND003 is that it is given topically and therefore
likely to more effectively deplete eosinophils in the lung. Other drugs
targeting eosinophils are given systemically, and are only partially
successful at eradicating eosinophils in the lung. Lung-resident eosinophils
play a critical role in severe asthma.
ND007 targets Th17 cells and is being developed for the treatment of chronic
inflammatory disorders. Numab is currently raising a series A financing to
advance ND003 and ND007 to their next value inflection points.
Numab has developed an ultra-high throughput procedure to identify extremely
rare molecules with powerful properties (e.g. with sub-picomolar affinities).
Moreover, Numab is able to engineer highly stable variable domains, which are
a prerequisite for the assembly of innovative protein therapeutics with
multiple specificities and predictable CMC properties.
Founded in 2011, Numab discovers and develops innovative antibody-based
therapeutics. Applying proprietary rabbit-based antibody discovery and
engineering technology, Numab generates highly potent and stable antibody Fv
fragments, which serve as building blocks to create mono- or bi-specific
antibody fragment-based therapeutics with tailored pharmacokinetic properties.
Numab’s therapeutic antibodies are designed to improve on existing therapies
in terms of effect size, effect duration and safety. For further information
CBO & co-CEO
Tel : +41 44 533 0471
Hans Herklots (media)
+41 79 598 7149
Press spacebar to pause and continue. Press esc to stop.